DrugPatentWatch Database Preview

Taro Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for TARO PHARMS, and what generic alternatives to TARO PHARMS drugs are available?

TARO PHARMS has eleven approved drugs.

There are four US patents protecting TARO PHARMS drugs.

There are nineteen patent family members on TARO PHARMS drugs in twelve countries and thirteen supplementary protection certificates in eight countries.

Summary for Taro Pharms

International Patents:	19
US Patents:	4
Tradenames:	10
Ingredients:	10
NDAs:	11

Drugs and US Patents for Taro Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Taro Pharms	CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE	benzoyl peroxide; clindamycin phosphate	GEL;TOPICAL	206218-001	Dec 15, 2017	AB	RX	No	No
Taro Pharms North	PSORCON	diflorasone diacetate	CREAM;TOPICAL	020205-001	Nov 20, 1992		DISCN	Yes	No
Taro Pharms	NAFTIFINE HYDROCHLORIDE	naftifine hydrochloride	CREAM;TOPICAL	206901-001	Jan 6, 2016	AB	RX	No	No
Taro Pharms	NAFTIFINE HYDROCHLORIDE	naftifine hydrochloride	CREAM;TOPICAL	205975-001	Sep 8, 2016		RX	No	Yes

Expired US Patents for Taro Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Taro Pharms	PLIAGLIS	lidocaine; tetracaine	CREAM;TOPICAL	021717-001	Jun 29, 2006	5,919,479
Taro Pharms	TOPICORT	desoximetasone	SPRAY;TOPICAL	204141-001	Apr 11, 2013	5,990,100

Paragraph IV (Patent) Challenges for TARO PHARMS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Topical Spray	0.25%		2013-12-18

Non-Orange Book US Patents for Taro Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
5,886,038	Composition and method for treatment of psoriasis

International Patents for Taro Pharms Drugs

Country	Document Number	Estimated Expiration
Germany	60032021
Israel	187666
World Intellectual Property Organization (WIPO)	0122907
World Intellectual Property Organization (WIPO)	2006130510

Supplementary Protection Certificates for Taro Pharms Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C/GB05/030	United Kingdom		PRODUCT NAME: NITISINONE (2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/303/001 20050221; UK EU/1/04/303/002 20050221; UK EU/1/04/303/003 20050221
2008000041	Germany		PRODUCT NAME: ADAPALEN IN KOMBINATION MIT BENZOYLPEROXID; NAT. REGISTRATION NO/DATE: 67913.00.00 20080229; FIRST REGISTRATION: DAENEMARK 40440 20071218
/1998	Austria		PRODUCT NAME: TAZAROTENE; NAT. REGISTRATION NO/DATE: 1-22102, 1-22103 19970918; FIRST REGISTRATION: DE 37393.00.00, 37393.01.00 19961203
C/GB98/002	United Kingdom		PRODUCT NAME: TAZAROTENE : ETHYL 6-(2-(4,4-DIMETHYLTHIOCHROMAN-6-YL) ETHYNYL) NICOTINOATE; REGISTERED: DE 37393.00.00 19961203; DE 37393.01.00 19961203; UK 00426/0097 19970730; UK 00426/0096 19970730

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Taro
• Taro Pharm
• Taro Pharm Inds
• Taro Pharm Inds Ltd